Pitcairn Co. Has $2.65 Million Stake in Haleon plc (NYSE:HLN)

Pitcairn Co. increased its holdings in shares of Haleon plc (NYSE:HLN) by 8.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 250,187 shares of the company’s stock after purchasing an additional 19,085 shares during the quarter. Pitcairn Co.’s holdings in Haleon were worth $2,647,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Fortitude Family Office LLC acquired a new position in Haleon during the third quarter worth $28,000. Cultivar Capital Inc. acquired a new position in Haleon during the second quarter worth $40,000. Hexagon Capital Partners LLC boosted its holdings in Haleon by 66.6% during the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after purchasing an additional 2,677 shares during the last quarter. Prospera Private Wealth LLC acquired a new position in Haleon during the third quarter worth $57,000. Finally, BOKF NA boosted its holdings in Haleon by 68.8% during the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on HLN shares. Berenberg Bank started coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley increased their price target on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon currently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Price Performance

Shares of HLN opened at $9.65 on Friday. The firm has a market capitalization of $43.68 billion, a PE ratio of 28.38, a PEG ratio of 2.88 and a beta of 0.30. The company’s 50-day moving average is $10.03 and its 200-day moving average is $9.37. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.